Your browser is no longer supported. Please, upgrade your browser.
Rockwell Medical, Inc.
Index- P/E- EPS (ttm)-0.43 Insider Own0.30% Shs Outstand93.57M Perf Week-10.32%
Market Cap134.89M Forward P/E- EPS next Y-0.29 Insider Trans-74.32% Shs Float86.80M Perf Month8.59%
Income-29.50M PEG- EPS next Q-0.09 Inst Own41.40% Short Float6.08% Perf Quarter39.70%
Sales62.50M P/S2.16 EPS this Y7.90% Inst Trans-8.00% Short Ratio2.59 Perf Half Y1.46%
Book/sh0.59 P/B2.36 EPS next Y25.60% ROA-46.30% Target Price- Perf Year-50.53%
Cash/sh0.69 P/C2.00 EPS next 5Y38.00% ROE-117.70% 52W Range0.83 - 3.85 Perf YTD37.62%
Dividend- P/FCF- EPS past 5Y-1.70% ROI- 52W High-63.90% Beta0.99
Dividend %- Quick Ratio5.80 Sales past 5Y2.50% Gross Margin5.50% 52W Low67.47% ATR0.14
Employees299 Current Ratio6.10 Sales Q/Q-0.60% Oper. Margin-44.30% RSI (14)46.84 Volatility8.75% 10.15%
OptionableYes Debt/Eq0.50 EPS Q/Q16.90% Profit Margin-47.20% Rel Volume0.47 Prev Close1.35
ShortableYes LT Debt/Eq0.50 Earnings- Payout- Avg Volume2.04M Price1.39
Recom2.00 SMA20-8.02% SMA507.92% SMA200-3.37% Volume949,846 Change2.96%
Jun-24-19Initiated Piper Jaffray Overweight $10
May-13-19Initiated H.C. Wainwright Buy $11
Nov-08-16Downgrade BofA/Merrill Neutral → Underperform
Mar-01-16Downgrade Stifel Buy → Hold
Aug-13-15Initiated Morgan Stanley Underweight $7
Jan-27-15Reiterated Oppenheimer Outperform $24 → $26
Jan-07-15Initiated Oppenheimer Outperform $24
Aug-14-14Initiated FBR Capital Underperform $6
Dec-19-13Initiated Chardan Capital Markets Buy $22
Nov-06-13Reiterated Summer Street Research Buy
Sep-05-13Reiterated Summer Street Research Buy $20 → $25
Aug-02-13Reiterated Summer Street Research Buy $20
Apr-11-12Initiated Summer Street Research Buy $20
Mar-12-12Initiated Stifel Nicolaus Buy $15
Jan-03-12Initiated Canaccord Genuity Buy $14
Dec-10-09Initiated JMP Securities Mkt Outperform $11
Oct-12-09Initiated Wedbush Morgan Outperform $12
Feb-09-21 01:45PM  
Feb-01-21 08:08AM  
Jan-14-21 08:47AM  
Jan-13-21 07:00AM  
Jan-05-21 07:00AM  
Dec-16-20 07:00AM  
Dec-02-20 04:07AM  
Nov-29-20 04:57PM  
Nov-09-20 05:02PM  
Nov-02-20 12:30PM  
Oct-27-20 08:00AM  
Oct-13-20 08:00AM  
Sep-24-20 06:09PM  
Sep-23-20 08:45AM  
Sep-22-20 09:52AM  
Sep-21-20 03:30PM  
Sep-15-20 07:59AM  
Sep-11-20 10:09AM  
Sep-10-20 09:52AM  
Sep-09-20 04:15PM  
Sep-08-20 08:00AM  
Aug-27-20 02:49PM  
Aug-10-20 06:35PM  
Aug-03-20 04:05PM  
Jun-17-20 08:43AM  
Jun-10-20 04:30PM  
May-27-20 12:43PM  
May-26-20 07:00AM  
May-11-20 08:05PM  
May-07-20 12:30PM  
Apr-20-20 08:30AM  
Mar-31-20 04:30PM  
Mar-27-20 11:21AM  
Mar-25-20 04:01PM  
Mar-22-20 02:25PM  
Mar-20-20 08:30AM  
Mar-18-20 09:42AM  
Mar-17-20 06:50AM  
Mar-16-20 08:00AM  
Mar-12-20 07:05PM  
Mar-11-20 08:30AM  
Mar-10-20 09:19AM  
Mar-09-20 04:53PM  
Mar-05-20 12:30PM  
Mar-04-20 04:30PM  
Feb-27-20 06:50AM  
Feb-11-20 12:30PM  
Feb-10-20 08:05AM  
Feb-06-20 04:30PM  
Feb-04-20 09:21AM  
Feb-03-20 04:01PM  
Jan-15-20 08:22AM  
Jan-14-20 09:30PM  
Jan-09-20 05:30PM  
Jan-08-20 04:30PM  
Dec-12-19 10:10AM  
Nov-21-19 06:50AM  
Nov-20-19 06:50AM  
Nov-11-19 05:25PM  
Nov-07-19 04:30PM  
Nov-04-19 06:50AM  
Nov-01-19 10:30AM  
Oct-31-19 04:30PM  
Oct-24-19 04:31PM  
Oct-21-19 09:00AM  
Oct-08-19 02:58PM  
Sep-24-19 04:30PM  
Sep-19-19 11:54AM  
Sep-05-19 04:30PM  
Aug-30-19 10:19AM  
Aug-28-19 04:30PM  
Aug-10-19 12:23AM  
Aug-08-19 08:00PM  
Aug-06-19 10:48AM  
Aug-01-19 10:33AM  
Jul-31-19 12:01PM  
Jul-29-19 04:30PM  
Jun-26-19 09:30PM  
Jun-25-19 01:47PM  
Jun-18-19 11:09AM  
Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis. It is also developing an intravenous formulation of Triferic for use by hemodialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1994 and is based in Wixom, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Richmond David S.10% OwnerDec 21Sale1.0342,45043,7241,433,309Dec 23 05:28 PM
Richmond David S.10% OwnerDec 16Sale1.01521,876529,64961,278Dec 17 09:59 PM
Richmond David S.10% OwnerDec 15Sale1.11278,124307,5051,611,780Dec 17 09:59 PM
Richmond David S.10% OwnerJun 30Buy1.9219,81338,088103,781Jul 02 03:37 PM
Richmond David S.10% OwnerJun 30Buy1.954,8689,475183,907Jul 02 03:37 PM
ELLISON RUSSELL HSee RemarksMay 14Buy2.082,0004,16012,050May 14 05:31 PM